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Abstract: Sugar consumption is associated with a whole range of negative health effects and should
be reduced and the natural sweetener xylitol might be helpful in achieving this goal. The present
study was conducted as a randomized, placebo-controlled, double-blind, cross-over trial. Twelve
healthy, lean volunteers received intragastric solutions with 7, 17 or 35 g xylitol or tap water on four
separate days. We examined effects on: gut hormones, glucose, insulin, glucagon, uric acid, lipid
profile, as well as gastric emptying rates, appetite-related sensations and gastrointestinal symptoms.
We found: (i) a dose-dependent stimulation of cholecystokinin (CCK), active glucagon-like peptide-1
(aGLP-1), peptide tyrosine tyrosine (PYY)-release, and decelerated gastric emptying rates, (ii) a
dose-dependent increase in blood glucose and insulin, (iii) no effect on motilin, glucagon, or glucose-
dependent insulinotropic peptide (GIP)-release, (iv) no effect on blood lipids, but a rise in uric acid,
and (v) increased bowel sounds as only side effects. In conclusion, low doses of xylitol stimulate the
secretion of gut hormones and induce a deceleration in gastric emptying rates. There is no effect
on blood lipids and only little effect on plasma glucose and insulin. This combination of properties
(low-glycemic sweetener which stimulates satiation hormone release) makes xylitol an attractive
candidate for sugar replacement.
Keywords: xylitol; natural sweeteners; gut hormones; appetite-related sensations; gastric emptying;
gastrointestinal symptoms; blood lipids; uric acid
1. Introduction
Sugar consumption should be reduced in the general population according to WHO
guidelines [1]. Individuals with diabetes and obesity are recommended a sugar-free,
low glycemic diet. In this context, sugar substitutes, such as low-calorie sweeteners
(LCS), might be helpful. However, a broad variety of substances are used and there is
increasing evidence that the physiological effect of each substance on the human body
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has to be studied separately rather than evaluating them as a group, as sweeteners differ
considerably in their chemical structure and their physiological properties, e.g., effects on
taste perception, release of gut hormones, influence on gut microbiota composition, and
stimulation of brain reward regions [2].
Xylitol is a simple alditol that is naturally occurring in various organisms and that has
a long history of use in a wide variety of foods and dental products. One gram of xylitol
provides around 2.4 kcal (compared to sucrose: 4 kcal/g), however xylitol is incompletely
absorbed, and the energy available to the human body is even lower. The major part
passes through the small intestine and is fermented by bacteria in the colon. As xylitol
is increasingly used as a sugar substitute, questions arise regarding metabolic effects in
humans, such as for instance release of gut hormones and satiating potential. A few studies
have been carried out in this context in the late 1980s. In 1987, Shafer et al. showed
that xylitol as part of a solid-food complex meal was able to decelerate gastric emptying
measured by scintigraphy [3] which indicates that xylitol impacts the satiation system. In
a trial published in 1989 by Salminen et al., oral administration of 30 g xylitol in 200 mL
water compared to 30 g glucose in 200 mL water also resulted in a deceleration in gastric
emptying [4]. Our own study group recently compared effects of acute intake of 75 g
glucose, 50 g xylitol or 75 g erythritol in 300 mL water versus placebo (tap water) on gut
hormones and gastric emptying. Fifty grams xylitol induced a significant retardation in
gastric emptying (GE), and led to a marked increase in plasma cholecystokinin (CCK) and
active glucagon-like-peptide 1 (aGLP-1) concentrations [5]. Potential side-effects known so
far include osmotic effects that can cause discomfort in some individuals in case of rapid
overconsumption. The load used in our preliminary study (50 g xylitol in 300 mL) led to
bloating and diarrhea in 60–70% of all subjects up to two hours after administration [5].
Other potential side effects associated with sweetener consumption are an increase in uric
acid and blood lipid concentrations [6,7], which has been associated with obesity and
metabolic syndrome [8]. The few studies that have investigated the effects of xylitol on
uric acid [9–12] and blood lipid [12–14] concentrations in humans so far show increased
concentrations in response to acute ingestion and mixed results after chronic exposure.
The primary objective of the present study was to determine whether a dose-dependent
effect in the release of CCK, aGLP-1 and PYY (peptide tyrosine tyrosine) can be observed
for xylitol. The secondary objectives were the effects on the secretion of motilin, GIP
(glucose-dependent insulinotropic peptide) and glucagon, as well as on gastric emptying
rates, in order to get a more complete picture of the effect of xylitol in the release of gut
hormones, the control of glycemic control, as well as its satiating potential. Finally, possible
side effects such as gastrointestinal symptoms, impact on uric acid and blood lipid profile
were also studied.
With this study we show that xylitol exhibits a combination of properties (weak
effect on blood sugar levels but significant release of satiation hormones) that render this
sweetener an attractive sugar substitute.
2. Materials and Methods
2.1. Study Approval
The protocol was approved by the Local Ethical Committee of Basel (Ethikkommis-
sion Nordwest- und Zentralschweiz (EKNZ): 2016-01928). The study was performed
in accordance with the principles of the Helsinki Declaration of 1975 as revised in 1983.
Each subject gave written informed consent for the study. The study was registered at
ClinicalTrials.gov (NCT03039478).
2.2. Subjects
A total of 12 normal weight, healthy participants (mean body-mass-index (BMI):
21.2 ± 0.4 kg/m2, range 19.4–23.0 kg/m2, 5 men and 7 female; mean age: 26.4 ± 1.5 years,
range 24–42 years) participated in the study. See participant flowchart (Appendix A:
flow diagram). Exclusion criteria included substance and alcohol abuse, regular intake
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of medications (except oral contraceptives), acute infections, chronic medical illness or
illnesses affecting the gastrointestinal system. None of the subjects had a history of food
allergies, dietary restrictions or pre-existing consumption of xylitol on a regular basis.
Weight, height and BMI were recorded for all participants.
2.3. Study Design and Experimental Procedure
This study was conducted as a randomized (counterbalanced), placebo-controlled,
double-blind, cross-over trial. On four separate occasions, at least 3 days apart and after a
10 h overnight fast, participants were admitted to the St. Clara Research Ltd., at ~0800 AM.
A feeding tube was placed transnasally, the intragastric position was confirmed by rapid
injection of 10 mL of air and auscultation of upper abdomen. The rationale for intragastric
administration of the nutrients was to bypass exteroceptive cues (e.g., taste and smell)
and associated hedonic responses and cognitions that may influence subjective ratings or
even physiological/endocrine responses [15]. An antecubital catheter was inserted into a
forearm vein for blood collection. The subjects were positioned in a comfortable sitting
position with their knees bent (80◦) and trunk upright.
After taking fasting blood (t = −10 and −1 min) and breath samples (t = −10), as well
as assessing appetite-related perceptions and GI symptoms before treatment, participants
received one of the following test solutions (at t = 0 min) directly into the stomach over
2 min in randomized order:
• 7 g xylitol dissolved in 300 mL tap water
• 17 g xylitol dissolved in 300 mL tap water
• 35 g xylitol dissolved in 300 mL tap water
• 300 mL tap water (placebo)
For the determination of the gastric emptying rates, 50 mg of 13C-sodium acetate
was added to the different test solutions. The intragastric infusions were freshly prepared
each morning of the study and were at room temperature when administered. The study
participant and the person who carried out all tests, as well as the personnel perform-
ing analysis of blood samples, were blinded concerning the content of the intragastric
infusion administered.
After the administration of the test solutions, blood samples (at t = 15, 30, 45, 60, 90,
120, and 180 min; for analysis of plasma CCK, aGLP-1, PYY, GIP, motilin, glucose, insulin,
and glucagon) and breath samples (at t = 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and
240 min; for analysis of gastric emptying rates) were taken. Extra blood samples were taken
during the visit with the highest xylitol load (35 g) at t = 30, 60, and 90 min for analysis of
serum total cholesterol, high- (HDL) and low-density lipoprotein (LDL), triglyceride and
uric acid concentrations.
Appetite-related sensations (hunger, prospective food consumption, satiety and full-
ness) were scored immediately after each blood collection by use of previously validated
visual analog scales (VASs) [16,17], which consist of a horizontal, unstructured, 10 cm line
with words anchored at each end, expressing the most positive and most negative rating
(e.g., for hunger: 0 cm: not at all hungry, 10 cm: as hungry as I have ever felt).
Participants were also asked to rate gastrointestinal symptoms at t = 30, 60, 90, 120, 150,
180, and 240 min after the administration of the test solutions. Gastrointestinal symptoms
were assessed by the use of a checklist including the following questions: (a) abdominal
pain, (b) nausea, (c) vomiting, (d) diarrhea, (e) borborygmus, (f) abdominal bloating, (g)
eruction and (h) flatulence. Participants were asked to choose between “no symptom” (0
points), “mild symptoms” (1 point) and “severe symptoms” (2 points) for each question at
each time point.
2.4. Materials
Xylitol was purchased from Mithana GmbH (Switzerland) and 13C-sodium acetate
from ReseaChem (Burgdorf, Switzerland).
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2.5. Blood Sample Collection and Processing
CCK, aGLP-1, PYY, and GIP blood samples were collected on ice into tubes containing
EDTA (6 µmol/L blood), a protease-inhibitor cocktail (Complete, EDTA-free, 1 tablet/50 mL
blood, Roche, Mannheim, Germany), and a dipeptidyl peptidase IV inhibitor (10 µL/mL
blood, Millipore Corp., St. Charles, Missouri, USA). Insulin, glucose, and glucagon blood
samples were collected on ice into tubes containing EDTA (6 µmol/L blood) and a protease-
inhibitor cocktail (Complete, EDTA-free, 1 tablet/50 mL blood, Roche, Mannheim, Ger-
many). Motilin blood samples were collected on ice into tubes containing lithium heparine
and a protease-inhibitor cocktail (Complete, EDTA-free, 1 tablet/50 mL blood, Roche,
Mannheim, Germany). Blood lipids and uric acid blood samples were collected on ice
into serum tubes. After centrifugation (4 ◦C at 3000 rpm for 10 min), plasma samples
were processed into different aliquots and serum samples left standing for 30 min before
they were processed into different aliquots as well. All samples were stored at −80 ◦C
until analysis.
2.6. Assessment of Gastric Emptying Rates
The gastric emptying rate was determined using a 13C-sodium acetate breath test,
an accurate, non-invasive method for measuring gastric emptying, without radiation
exposure, and a reliable alternative to scintigraphy, the current “gold standard” [18]. Test
solutions were labeled with 50 mg of 13C-sodium acetate, an isotope absorbed readily
in the proximal small intestine, next transported to the liver where it is metabolized to
13CO2, which is then exhaled rapidly [18]. At fixed time intervals, end-expiratory breath
samples were taken into a 100 mL foil bag. The 13C-exhalation was determined by non-
dispersive infrared spectroscopy usin g an isotope ratio mass spectrophotometer (Kibion®
Dynamic Pro; Kibion GmbH, Bremen, Germany), and expressed as the relative difference
(δ ‰) from the universal reference standard (carbon from Pee Dee Belemnite limestone).
13C-enrichment was defined as the difference between pre-prandial 13C-exhalation and
post-prandial 13C-exhalation at defined time points, δ over basal (DOB, ‰). Delta values
were converted into atom percent excess and then into percent of administered dose of 13C
excreted per hour (%dose/h (%)). Kinetics emptying was assessed by non-linear regression
analysis using the Origin 2019 Software (OriginLab Corp., Northampton, MA, USA) and
the modified Ghoos equation [18]:
y(t) = m · k · β · exp(−k · (t − t0))
·(1 − exp(−k · (t − t0)))(β−1)
(1)










where k and β are parameter of the curve, m denotes the extent of marker emptied, T10
and T50 denotes the times, were 10 and 50% of the marker is emptied, and t0 the lag-time
of gastric emptying. For goodness of fits, coefficient of determination, R2 are reported.
2.7. Laboratory Analysis
Plasma CCK: was measured with a sensitive radioimmunoassay using a highly specific
antiserum (No. 92128) [19]. The intra- and inter-assay variability is below 15%, respectively.
Plasma active GLP-1: was quantified using a non-radioactive high-sensitive sandwich
ELISA (Millipore EZGLPHS-35K) in the presence of a chemiluminescent substrate. The
intra- and inter-assay variability is below 9% and 13%, respectively.
Plasma PYY-3-36 and GIP: were measured with sandwich ELISA kits from Millipore
(Human GIP (total)-# EZHGIP-54K, Human PYY-3-36 (total)-# EZHPYYT66K). The intra-
and inter-assay variability for PYY is below 5.78% and 16.50%, respectively. The intra- and
inter-assay variability for GIP is below 8.8% and 6.1%, respectively.
Nutrients 2021, 13, 174 5 of 21
Plasma motilin: was measured as previously described using 125I (Nle13) human
motilin as tracer and rabbit anti-human Nle13 motilin antibody (final dilution 1/100000) [20].
The intra- and inter-assay variability is below 4.9% and 5.9%, respectively.
Plasma glucose: was measured by a glucose oxidase method (Rothen Medizinische
Laboratorien AG, Basel, Switzerland).
Plasma insulin: was quantified using a chemiluminescent microparticle immunoassay
(chemiflex) reagent kit (#8k41; Abbott) and the relative light units detected by the ARCHI-
TECT optical system (model: CI4100; Abbott). The ARCHITECT Insulin assay precision
is ≤7% total CV.
Plasma glucagon: was measured after extraction of plasma with 70% ethanol (vol/vol,
final concentration). The antibody is directed against the C-terminus of the glucagon
molecule (antibody code no. 4305) and therefore mainly measures glucagon of pancreatic
origin [21,22]. The intra- and inter-assay variability is below 6% and 15%, respectively.
Serum blood lipids (serum triglyceride, cholesterol, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL)): were measured with enzymatic assays from Beckman-
Coulter (Rothen Medizinische Laboratorien AG, Basel, Switzerland). The intra and inter-
assay variability is below 1.1% and 1.2% (triglyceride), below 0.8% and 1.1% (cholesterol),
below 0.9% and 0.9% (LDL), and below 1.0% and 1.8% (HDL).
Serum uric acid: was measured with an enzymatic assay from Beckman-Coulter
(Rothen Medizinische Laboratorien AG, Basel, Switzerland). The intra- and inter-assay
variability is below 0.7% and 0.8%.
2.8. Statistics
In our previous work investigating the effects of 50 g xylitol on gut hormone secretion
and gastric emptying rates, we did find significant results [5]. However, since pharma-
cological effects are usually not linear with respect to dose, we did not have a reliable
estimate of effect size for the current study, so no formal estimate of sample size could be
obtained. A sample size of 12 subjects per group was chosen for reasons of comparability
and practicability. In this respect, this study is a hypothesis-generating study that allows
descriptive data analysis.
Descriptive statistics were used for demographic variables such as age, weight, height
and BMI. For hormone and glucose profiles, as well as gastric emptying rates and appetite-
related sensations, incremental values were used to calculate area under the curve (iAUC)
by trapezoidal rule. Maximum and minimum deviations from baseline-iCmax and iCmin—
were determined on baseline-corrected data, as well. For AUC calculations, in addition to
the total time interval of 180 min, an interval of 60 min is reported as in some parameters
(CCK, aGLP-1) the main effect is seen in this time period. Linear mixed-effects modeling
was applied to describe differences between the different treatments (placebo, 7, 17 and 35 g
xylitol). In case of significant overall treatment effects, pairwise post-hoc within-subject
comparisons were done using Šidak multicomparison test. In addition, for the parameters
of interest (e.g., the iAUCs 0–60 min for CCK, aGLP-1 and PYY) the minimum detectable
differences were estimated on the basis of the observed data in the present study by a
simulation using the PASS 2020 Power Analysis and Sample Size Software (2020), NCSS,
LLC, Kaysville, UT, USA (using 1000 iterations per each run).
To explore putative relationships between different gut hormone responses (e.g., CCK,
aGLP-1, and PYY) and gastric emptying of the different treatments, the integrated responses
(iAUC 0–60 min) were correlated on an individual basis by linear matrix correlation. The
goodness of this correlation was expressed by Pearson’s correlation coefficient, R.
All statistical analysis was done using the statistical software package IBM SPSS
Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. Values were reported as
means ± standard deviation (SD), and displayed in figures as means ± standard error of
mean (SEM). Differences were considered to be statistically significant when p < 0.05.
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3. Results
All subjects tolerated the study well and there were no adverse events that would
have led to study discontinuation. Complete data from 12 participants were available
for analysis.
3.1. Fasting Values
For each measured parameter, fasting values were compared between the treatments.
None of these parameters were statistically significant between the treatments.
3.2. Gut Hormone Secretion
Plasma CCK: Xylitol leads to a dose-dependent increase in plasma CCK concentrations
compared to placebo. There was an overall statistically significant difference comparing
iAUC 0–60 min (p < 0.001). Pairwise comparison revealed statistically significant difference
for placebo vs. 17 g xylitol (p < 0.001), placebo vs. 35 g xylitol (p = 0.002), 7 vs. 17 g xylitol
(p = 0.009), and 7 vs. 35 g xylitol (p = 0.010). Overall statistical significance was also reached
for iAUC 0–180 min (p = 0.026). Pairwise comparisons revealed statistically significant
difference for placebo vs. 35 g xylitol (p = 0.023). Further, there was an overall statistically
significant difference comparing iCmax (p < 0.001): pairwise significant differences were
observed between placebo vs. 17 g xylitol (p < 0.001), placebo vs. 35 g xylitol (p = 0.002),
7 vs. 17 g xylitol (p = 0.009), and 7 vs. 35 g xylitol (p = 0.010) (Figure 1A, Table 1).
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Plasma aGLP-1: Xylitol leads to a dose-dependent increase in plasma aGLP-1 con-
centrations compared to placebo. There was an overall statistically significant difference
comparing iAUC 0–60 min (p = 0.002). Pairwise comparison revealed statistically signifi-
cant difference for placebo vs. 17 g xylitol (p = 0.008), and placebo vs. 35 g xylitol (p = 0.006).
Further, there was an overall statistically significant difference comparing iCmax (p = 0.002):
pairwise significant differences were observed between placebo vs. 17 g xylitol (p = 0.013),
and placebo vs. 35 g xylitol (p = 0.003) (Figure 1B, Table 1).
Plasma PYY: Xylitol leads to a dose-dependent increase in plasma PYY concentrations
compared to placebo. There was an overall statistically significant difference comparing
iAUC 0–60 min (p < 0.001). Pairwise comparison revealed statistically significant difference
for placebo vs. 35 g xylitol (p = 0.002), 7 vs. 35 g xylitol (p < 0.001), and 17 vs. 35 g xylitol
(p = 0.005). Overall statistical significance was also reached for iAUC 0–180 min (p = 0.004).
Pairwise comparisons revealed statistically significant difference for placebo vs. 35 g xylitol
(p = 0.003), 7 vs 35 g xylitol (p = 0.015), and 17 vs. 35 g xylitol (p = 0.007). Further, there
was an overall statistically significant difference comparing iCmax (p = 0.001): pairwise
significant differences were observed between placebo vs. 7 g xylitol (p = 0.030), placebo vs.
35 g xylitol (p = 0.002), and 17 vs. 35 g xylitol (p = 0.024). (Figure 1C, Table 1).
Plasma GIP: No effect of xylitol treatment on plasma GIP concentrations could be
found: the values of iAUC 0–60 min, iAUC 0–180 min and iCmin did not show any overall
statistically significant differences (Figure 1D, Table 1).
Plasma motilin: No effect of xlylitol treatment on plasma motilin concentrations could
be found: the values of iAUC 0–60 min, iAUC 0–180 min and iCmin did not show any
overall statistically significant differences (Figure 1E, Table 1).
3.3. Minimum Detectable Difference
Based on the results of this study, the minimum detectable differences were estimated
for the incremental AUCs 0–60 min for CKK, aGLP-1 and PYY. The minimum detectable
difference for CCK was 68.0 pmol × min/L, for aGLP-1 162 pmol × min/L, and finally for
PYY 332 pmol × min/L with a corresponding statistical power (95% confidence interval)
of 80.7% (78.1–83.1%), 80.9 % (78.3–83.3%) and 82.3% (79.8–84.6%), respectively. These data
correspond well with the applied statistical tests.
3.4. Dose–Response Evaluation
For CCK, aGLP-1 and PYY the dose–response relationship was evaluated and shown
in Figure 1F. On average, all these hormones showed a monotonically increasing curvilinear
secretion with increasing xylitol dose. For none of the hormones an apparent saturation
of the stimulating effect was observed, so that no half-maximal stimulating dose (ED50)
could be estimated.
3.5. Gastric Emptying
Xylitol leads to a dose-dependent deceleration of gastric emptying rates compared
to placebo (Figure 2, Table 2). There was an overall statistically significant difference
comparing T50% (p = 0.026). Pairwise comparisons revealed that time needed to empty
50% of the dose was significantly shorter for placebo vs. 35 g xylitol (56.6 ± 13.0 min vs.
74.0 ± 18.1 min; p = 0.029). Goodness of fit parameter R2 were between 0.992 and 0.999 for
all treatments.
Nutrients 2021, 13, 174 8 of 21
Table 1. Effect of xylitol on plasma concentrations of CCK, aGLP-1, PYY, GIP and motilin.
Parameters A: Placebo(n = 12)
B: Xylitol 7 g
(n = 12)
C: Xylitol 17 g
(n = 12)







Fasting values (pmol/L) 1.1 ± 0.8 1.0 ± 0.6 1.0 ± 1.1 0.9 ± 0.7 NS
iAUC (0–60 min) (pmol × min/L) 0.6 ± 32.6 12.1 ± 27.6 71.8 ± 30.2 150.8 ± 102.8 p < 0.001
A vs. C: p < 0.001
A vs. D: p = 0.002
B vs. C: p = 0.009
B vs. D: p = 0.010
iAUC (0–180 min) (pmol × min/L) −29.2 ± 108.9 27.1 ± 112.4 49.7 ± 89.4 222.2 ± 187.6 p = 0.026 A vs. D: p = 0.023
iCmax (pmol/L) 0.6 ± 0.6 1.4 ± 1.1 3.0 ± 1.2 5.1 ± 3.1 p < 0.001
A vs. C: p < 0.001
A vs. D: p = 0.002
B vs. C: p = 0.009
B vs. D: p = 0.010
Tmax (min) 40.0 ± 52.1 32.5 ± 41.4 15.0 ± 0.0 25.0 ± 30.2 NS
iCmin (pmol/L) −0.7 ± 0.6 −0.5 ± 0.4 −0.6 ± 0.7 −0.2 ± 0.4 NS
Tmin (min) 90.0 ± 56.1 113.8 ± 74.4 127.5± 62.8 80.0 ± 86.1 NS
aGLP
Fasting values (pmol/L) 3.6 ± 1.9 4.9 ± 2.5 5.0 ± 3.4 5.9 ± 3.8 NS
iAUC (0–60 min) (pmol × min/L) 66.5 ± 119.1 160.6 ± 170.2 254.7 ± 182.2 447.0 ± 332.1 p = 0.002 A vs. C: p = 0.008A vs. D: p = 0.006
iAUC (0–180 min) (pmol × min/L) 71.8 ± 269.4 53.6 ± 392.4 215.1 ± 330.4 553.5 ± 612.8 NS
iCmax (pmol/L) 3.5 ± 2.8 6.9 ± 5.4 8.2 ± 4.2 13.0 ± 7.3 p = 0.002 A vs. C: p = 0.013A vs. D: p = 0.003
Tmax (min) 31.3 ± 49.3 28.8 ± 30.3 25.0 ± 14.8 28.8 ± 30.3 NS
iCmin (pmol/L) −1.4 ± 1.0 −2,5 ± 2.5 −2.1 ± 2.5 −1.9 ± 2.6 NS
Tmin (min) 98.8 ± 60.2 112.5 ± 69.0 91.3 ± 79.0 105.0 ± 84.4 NS
PYY
Fasting values (pmol/mL) 18.7 ± 6.3 17.0 ± 6.8 20.5 ± 9.2 17.2 ± 6.2 NS
iAUC (0–60 min) (pmol × min/L) 5.6 ± 240.0 159.3 ± 241.4 263.1 ± 380.6 780.8 ± 378.6 p < 0.001
A vs. D: p = 0.002
B vs. D: p < 0.001
C vs. D: p = 0.005
iAUC (0–180 min) (pmol × min/L) −256.5 ± 775.1 537.1 ± 935.6 835.9 ± 1420.4 3148.2 ± 2037.9 p = 0.004
A vs. D: p = 0.003
B vs. D: p < 0.015
C vs. D: p = 0.007
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Table 1. Cont.
Parameters A: Placebo(n = 12)
B: Xylitol 7 g
(n = 12)
C: Xylitol 17 g
(n = 12)






iCmax (pmol/L) 5.1 ± 3.6 13.3 ± 7.4 12.5 ± 8.9 25.7 ± 12.4 p = 0.001
A vs. B: p = 0.030
A vs. D: p = 0.002
C vs. D: p = 0.024
Tmax (min) 30.0 ± 15.7 91.4 ± 47.6 72.3 ± 54.4 88.8 ± 72.8 p < 0.001 A vs. B: p = 0.009
iCmin (pmol/L) −8.4 ± 6.6 −6.9 ± 6.7 −4.4 ± 5.9 −0.3 ± 0.8 p = 0.007 A vs. D: p = 0.012
Tmin (min) 115.0 ± 52.5 111.8 ± 82.0 47.7 ± 63.9 30.0 ± 70.1 p = 0.030 A vs. D: p = 0.047
GIP
Fasting values (pmol/L) 17.6 ± 7.67 18.12 ± 8.93 17.51 ± 7.16 17.36 ± 5.44 NS
iAUC (0–60 min) (pmol × min/L) −120.8 ± 295.6 −160.92 ± 234.1 −307.6 ± 194.2 −138.2 ± 191.8 NS
iAUC (0–180 min) (pmol × min/L) −710.9 ± 1186.3 −749.4 ± 925.1 −990.7 ± 815.0 −871.5 ± 727.1 NS
iCmax (pmol/L) 3.1 ± 4.6 3.0 ± 3.1 3.2 ± 4.3 3.1 ± 3.5 NS
Tmax (min) 37.5 ± 43.6 56.3 ± 58.7 65.0 ± 70.7 30.0 ± 53.5 NS
iCmin (pmol/L) −8.9 ± 6.3 −9.2 ± 6.3 −10.8 ± 5.3 −8.7 ± 4.3 NS
Tmin (min) 122.5 ± 62.9 117.5 ± 67.3 102.5 ± 54.6 123.8 ± 46.2 NS
Motilin
Fasting values (pg/mL) 483 ± 136 470 ± 79 489 ± 108 428 ± 136 NS
iAUC (0–60 min) (pg × min/mL) 1957 ± 6146 3392 ± 3231 896 ± 4037 2973 ± 4027 NS
iAUC (0−180 min) (pg × min/mL) −182 ± 10963 4091 ± 6991 −1493 ± 11287 8074 ± 11825 NS
iCmax (pg/mL) 117.3 ± 116.6 165.6 ± 92.0 119.0 ± 79.2 131.4 ± 75.6 NS
Tmax (min) 40.0 ± 23.4 43.8 ± 54.4 36.3 ± 37.5 52.5 ± 53.3 NS
iCmin (pg/mL) −81.9 ± 51.8 −67.8 ± 33.9 −102.3 ± 78.5 −45.0 ± 45.0 NS
Tmin (min) 2.3 ± 56.3 21.8 ± 76.9 30.5 ± 91.7 45.4 ± 76.1 NS
Data are expressed as mean ± SD and reported from baseline (incremental). Statistical tests: Linear mixed-effects modeling followed by Šidak post-hoc test in case of overall significance. aGLP-1, active
glucagon-like peptide-1; CCK, cholecystokinin; GIP, glucose-dependent insulinotropic peptide; PYY, peptide tyrosine tyrosine.
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Figure 2. Effect of xylitol on gastric emptying. Data are expressed as mean ± SEM. N=12 (5 men
and 7 women). Kinetic data was analyzed by non-linear regression analysis using a modified
Ghoose model for gastric emptying [18]. Statistical tests: Linear mixed-effects modeling followed
by Šidak post-hoc test in case of overall significance. Goodness of fit is indicated by the coefficient
of determination R2: placebo R2 = 0.992, 7 g xylitol R2 = 0.995, 17 g xylitol R2 = 0.995, 35 g xylitol
R2 = 0.999. Re ults of the statistical analysis are shown in Table 2.
Table 2. Effect of xylitol on gastric emptying.
A: Placebo
(n = 12)
B: Xylitol 7 g
(n = 12)
C: Xylitol 17 g
(n = 12)







(dose × min/h) 911 ± 129 917 ± 101 814 ± 164 823 ± 154 NS
iAUC (0–180 min)
(dose × min/h) 1609 ± 270 1733 ± 221 1614 ± 319 1767 ± 302 NS
Tmax (min) 21.25 ± 7.7 21.25 ± 7.7 27.50 ± 5.8 30.00 ± 11.1 p = 0.039 B vs. C:p = .099
T50% (time 50%
emptied) (min) 56.6 ± 13.0 65.3 ± 11.1 66.9 ± 13.3 74.0 ± 18.1 p = 0.026
A vs. D:
p = .029
Data are expressed as mean ± SD and reported from baseline (incremental). Linear mixed-effects modeling followed by Šidak post-hoc test
in case of overall.
3.6. Correlations Gastric Emptyimg Rates and Gut Hormone Concentrations
CCK, aGLP-1 and PYY were weakly linear correlated to gastric emptying (R = −0.041,
R = 0.128 and R = 0.158, respectively) (Figure 3).
3.7. Appetite-Realted Sensations
Appetite-related sensations: No effect of xylitol treatment on appetite-related sensa-
tions could be found: The values of iAUC 0–60 min, iAUC 0–180 min and iCmax did not
show any overall statistically significant differences (Figure 4A–D).
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tween placebo vs. 17 g xylitol (p < 0.001), and placebo vs. 35 g xylitol (p = 0.001) (Figure 5A, 
Table 3). 
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0.001): pairwise significant differences were observed between placebo vs. 17 g xylitol (p = 
0.030), placebo vs. 35 g xylitol (p < 0.001), 7 vs. 35 g xylitol (p = 0.001), and 17 vs. 35 g xylitol (p 
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Plasma glucagon: There was an overall statistically significant difference comparing iC-
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Figure 4. (A) hunger, (B) prospective food consumption, (C) satiety, and (D) fullness. Data are
expressed as mean ± SEM, baseline values are reported. N = 12 (5 m n and 7 women). Statistical
tests: Line r mixed-effects modeling followed by Šidak post-hoc test in case of overall significance.
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3.8. Plasma Glucose, Insulin and Glucagon Release
Plasma glucose: Xylitol leads to a dose-dependent increase in plasma glucose con-
centrations compared to placebo. There was an overall statistically significant difference
comparing iAUC 0–60 min (p < 0.001). Pairwise comparison revealed statistically significant
difference for placebo vs. 17 g xylitol (p < 0.001). Further, there was an overall statistically
significant difference comparing iCmax (p < 0.001): pairwise significant differences were
observed between placebo vs. 17 g xylitol (p < 0.001), and placebo vs. 35 g xylitol (p = 0.001)
(Figure 5A, Table 3).
Plasma insulin: Xylitol leads to a dose-dependent increase in plasma insulin con-
centrations compared to placebo. There was an overall statistically significant difference
comparing iAUC 0–60 min (p < 0.001). Pairwise comparison revealed statistically signifi-
cant difference for placebo vs. 17 g xylitol (p < 0.001), placebo vs. 35 g xylitol (p < 0.001),
7 vs. 35 g xylitol (p = 0.001), and 17 vs. 35 g xylitol (p = 0.004). Overall statistical signifi-
cance was also reached for iAUC 0–180 min (p = 0.008). Pairwise comparisons revealed
statistically significant difference for placebo vs. 35 g xylitol (p = 0.010), 7 vs. 35 g xylitol
(p = 0.006), and 17 vs. 35 g xylitol (p = 0.008). Further, there was an overall statistically
significant difference comparing iCmax (p < 0.001): pairwise significant differences were
observed between placebo vs. 17 g xylitol (p = 0.030), placebo vs. 35 g xylitol (p < 0.001),
7 vs. 35 g xylitol (p = 0.001), and 17 vs. 35 g xylitol (p = 0.036) (Figure 5B, Table 3).




Figure 5. (A) glucose, (B) insulin, and (C) glucagon. Data are expressed as mean ± SEM, absolute values are reported. N=12 (5 
men and 7 women). Statistical tests: Linear mixed-effects modeling followed by Šidak post-hoc test in case of overall signifi-
cance. Results of the statistical analysis are shown in Table 3. 
Figure 5. (A) glucose, (B) insulin, and (C) glucagon. Data are express d as mean ± SEM, absolute
values are reported. N=12 (5 men and 7 women). Statistical tests: Linear mixed-effects modeling
followed by Šidak post-hoc test in case of overall significance. Results of the statistical analysis are
shown in Table 3.
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Table 3. Effect of xylitol on plasma concentrations of glucose, insulin and glucagon.
Parameters A: Placebo(n = 12)
B: Xylitol 7 g
(n = 12)
C: Xylitol 17 g
(n = 12)








(mmol/L) 4.9 ± 0.3 4.8 ± 0.4 4.7 ± 0.5 4.9 ± 0.4 NS
iAUC (0–60 min)
(mmol × min/L) −4.5 ± 4.0 6.8 ± 18.6 18.2 ± 0.3 15.5 ± 22.3 p < 0.001 A vs. C: p < 0.001
iAUC (0–180 min)
(mmol × min/L) −8.4 ± 14.1 −8.3 ± 56.4 12.8 ± 35.4 −1.0 ± 49.4 NS
iCmax (mmol/L) 0.07 ± 0.1 0.37 ± 0.33 0.55 ± 0.21 0.67 ± 0.39 p < 0.001 A vs. C: p < 0.001A vs. D: p = 0.001
Tmax (min) 43.8 ± 48.9 31.3 ± 47.6 23.8 ± 10.0 22.5 ± 15.0 NS
iCmin (mmol/L) −0.19 ± 0.07 −0.23 ± 0.25 −0.21 ± 0.16 −0.44 ± 0.31 NS
Tmin (min) 55.0 ± 55.9 50.0 ± 54.0 102.5 ± 62.0 97.5 ± 59.8 NS
Insulin
Fasting values
(mmol/L) 0.033± 0.012 0.031 ± 0.009 0.028 ± 0.010 0.032 ± 0.011 NS
iAUC(0–60 min)
(mmol × min/L) −0.1 ± 0.4 0.3 ± 0.4 0.7 ± 0.4 2.0 ± 1.1 p < 0.001
A vs. C: p < 0.001
A vs. D: p < 0.001
B vs. D: p = 0.001
C vs. D: p = 0.004
iAUC (0–180 min)
(mmol × min/L) −0.6 ± 1.2 −0.18 ± 0.3 0.3 ± 0.95 2.9 ± 2.5 p = 0.008
A vs. D: p = 0.010
B vs. D: p = 0.006
C vs. D: p = 0.008
iCmax (mmol/L) 0.01 ± 0.01 0.02 ± 0.01 0.03 ± 0.03 0.07 ± 0.02 p < 0.001
A vs. C: p = 0.030
A vs. D: p < 0.001
B vs. D: p = 0.001
C vs. D: p = 0.036
Tmax (min) 41.3 ± 66.8 20.0 ± 22.5 15.0 ± 0.0 25.0 ± 14.8 NS
iCmin (mmol/L) −0.01 ± 0.01 −0.01 ± 0.01 −0-01 ± 0-011 −0.01 ± 0.01 NS
Tmin (min) 96.3 ± 72.8 88.8 ± 67.2 118.8 ± 77.9 126.3 ± 73.9 NS
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Table 3. Cont.
Parameters A: Placebo(n = 12)
B: Xylitol 7 g
(n = 12)
C: Xylitol 17 g
(n = 12)








(pmol/L) 5.54 ± 1.50 5.00 ± 2.35 5.83 ± 2.42 4.92 ± 1.74 NS
iAUC (0–60 min)
(pmol × min/L) −20.3 ± 78.9 −3.1 ± 64.7 −32.5 ± 36.8 34.4 ± 62.2 NS
iAUC (0–180 min)
(pmol × min/L) −154.1 ± 268.1 −9.4 ± 233.6 −102.5 ± 147.7 11.88 ± 170.4 NS
iCmax (pmol/L) 1.04 ± 1.14 1.25 ± 0.78 0.75 ± 0.45 1.92 ± 0.97 p = 0.011 C vs D: p = 0.012
Tmax (min) 22.5 ± 18.6 31.3 ± 38.1 50.0 ± 39.1 75.0 ± 56.1 p = 0.018 A vs D: p = 0.082
iCmin (pmol/L) −2.00 ± 1.28 −1.54 ± 1.53 −1.75 ± 1.06 1.83 ± 0.86 NS
Tmin (min) 52.8 ± 34.1 56.38 ± 52.1 537 ± 52.1 46.3 ± 47.6 NS
Data are expressed as mean ± SD and reported from baseline (incremental). Statistical tests: Linear mixed-effects modeling followed by Šidak post-hoc test in case of overall significance.
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Plasma glucagon: There was an overall statistically significant difference comparing
iCmax (p = 0.011). Pairwise comparison revealed statistically significant difference for
17 vs. 35 g xylitol (p = 0.012).
3.9. Impact on Blood Lipid Profil, Uric Acid and Gastrointestinal Symptoms
Blood lipids: There was no statistically significant increase from baseline in blood
lipids (total cholesterol, LDL, HDL and triglycerides) within 120 min after 35 g xylitol. Mean
fasting concentration of total cholesterol was 4.2 ± 0.2 mmol/L (Cmax 4.4 ± 0.2 mmol/L),
LDL2.5 ± 0.2 mmol/L(Cmax2.5 ± 0.2 mmol/L), HDL1.4± 0.1mmol/L(Cmax1.5± 0.1mmol/L),
and triglycerides 0.9±0.1 mmol/L (Cmax 0.9±0.1 mmol/L) (data not shown).
Uric acid: There was a statistically significant increase from baseline in uric acid
concentrations after 35 g xylitol (p < 0.001). Mean fasting concentration uric acid was
271.1 ± 22.8 µmol/L (Cmax 376.2 ± 23.6 mmol/L) (Figure 6).
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mean ± SEM, absolute values are reported. N = 12 (5 men and 7 women). Statistical tests: Linear
mixed-effects modeling followed by Šidak post-hoc t st in case of overall significance.
Gastrointestinal symptoms: There was no abdominal pain, nausea, vomiting, diarrhea,
or flatulence after any dose and no difference between xylitol and placebo was found. In
five participants after placebo, nine participants after 7 g, eight participants after 17 g and
nine participants after 35 g xylitol a subjective increase in bowel sounds was reported (max.
reported severity 1.4 after placebo), and two volunteers described an increased feeling of
bloating after 17 g and 35 g xylitol (maximum reported severity 1.0). One volunteer had
eructation after 7 g (reported severity 1.0) (Table 4).
4. Discussion
The main results of the study can be summarized as follows: (i) xylitol induces a
dose-dependent stimulation of CCK, aGLP-1, and PYY release, and deceleration of gastric
emptying rates, (ii) xylitol leads to a dose-dependent increase in blood glucose and insulin
concentrations, (iii) xylitol has no effect on motilin, glucagon or GIP-release, (iv) blood
lipids are not affected by 35 g xylitol, but a rise in uric acid is observed, and (v) doses up to
35 g xylitol are well tolerated.
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Table 4. Assessment of gastrointestinal symptoms.
Placebo (n = 12) Xylitol 7 g (n = 12) Xylitol 17 g (n = 12) Xylitol 35 g (n = 12)
Abdominal pain No of subjects with symptom 0 0 0 0
max severity * - - - -
Nausea No of subjects with symptom 0 0 0 0
max severity - - - -
Vomiting No of subjects with symptom 0 0 0 0
max severity - - - -
Diarrhea No of subjects with symptom 0 0 0 0
max severity - - - -
Bowel sounds No of subjects with symptom 5 9 8 9
max severity 1.4 1.0 1.25 1.0
Bloating No of subjects with symptom 0 0 1 1
max severity - - 1.0 1.0
Eructation No of subjects with symptom 0 1 0 0
max severity - 1.0 - -
Flatulence No of subjects with symptom 0 0 0 0
max severity - - - -
* severity score 1 = mild; 2 = severe. Gastrointestinal symptoms were assessed by the use of a checklist. Participants were asked to choose between “no symptom” (0 points), “mild symptoms“ (1 point) and
“severe symptoms” (2 points) for each item.
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The gastrointestinal tract plays an important role in regulating appetite and satiation
and thus maintaining energy balance. Nutrient components such as carbohydrates, fats and
amino acids are recognized by receptors located on enteroendocrine cells in the intestinal
tract, which stimulate the release of gut hormones such as CCK, GLP-1, PYY, and GIP.
These hormones are able to activate a whole range of satiation mechanisms, including
deceleration of gastric emptying [23,24].
Xylitol provides around half the calories of sucrose per gram. However, most of
the substance ingested is never absorbed and the bioavailability is therefore significantly
lower. Nevertheless, in our previous trial with 50 g xylitol we could show for the first
time, that the satiation cascade is stimulated: although low in calories, xylitol leads to a
strong increase in the gut hormones CCK and GLP-1, and subsequently delays gastric
emptying [5]. Other low- or non-caloric sweeteners (e.g., aspartame, acesulfame-K and
sucralose) have no stimulating effect on gut hormone release in vivo [25–27]. With the
present study we substantiate that xylitol induces a rise in plasma gut hormones and delays
gastric emptying and expand these findings by showing a stimulation of CCK, aGLP-1 and
PYY in a dose-dependent manner. Gastric emptying is regulated by numerous feedback
mechanisms, including gut hormone release such as CCK and GLP-1 [23,24]. In this trial,
xylitol induced a deceleration of gastric emptying which is at least partly mediated via the
gut hormones as we were able to show that CCK, aGLP-1 and PYY correlated to gastric
emptying. The underlying mechanism of the xylitol induced gut hormone secretion is
not clear yet, however, we infer from these observations that the ability of sweeteners to
induce a secretion of gut hormones is sweetener-specific, irrespective of its caloric value. A
recent publication indicates that increase in duodenal osmolarity by administration of a
hyperosmolar saline solution is also associated with an increase in CCK, GLP-1 and PYY
concentrations, while GIP and glucagon are not affected [28]. Whether osmolarity plays a
role in the xylitol-stimulated gut hormone release is not known at this point. In our trial,
the solution with the lowest concentration (7 g) was hypoosmolar (153.34 mOsmol/L), yet
clearly stimulated CCK and GLP-1 release. We therefore assume that osmolarity alone is
not responsible for the xylitol-stimulated release of gut hormones.
In our trial, we have also investigated the effect of xylitol on plasma motilin con-
centrations, another gut hormone involved in the control of appetite and food intake.
Plasma motilin concentrations fluctuate in synchrony with the phases of the migrating
motor complex, and reach a peak just before the occurrence of a gastric phase III [29–31].
Motilin-induced gastric phase III contractions signal hunger and plasma motilin concen-
trations are closely associated with interdigestive hunger ratings [32]. In a recent study
we investigated the effect of two caloric sweeteners—glucose and fructose—versus the
non-caloric sweetener acesulfam-K on plasma motilin concentrations and showed that
glucose and fructose inhibited motilin secretion, which can be interpreted as a satiation
signal [27]. In contrast, acesulfam-K had no inhibitory effect on motilin. In the present
study, the effect of xylitol on motilin concentrations was not different from tap water. This
combination of properties—stimulation of gut hormones such as CCK, GLP-1, and PYY,
but no inhibition of motilin—means that xylitol occupies an intermediate position between
caloric- and non-caloric sweeteners. In 1989, Salminen et al. [4] compared 30 g glucose
vs. 30 g xylitol ingestion on gastric emptying, GIP and motilin release. They described an
early (at 20 min), transient but significant increase in plasma motilin concentrations after
xylitol intake. However, in our current trial as well as in the study carried out by Salminen
et al., no gastroduodenal manometry was performed, which would have allowed to adjust
motilin measurements around a phase III of the MMC. Therefore, the question whether
xylitol has an inhibitory or a stimulating effect on motilin release is still not clear and needs
to be addressed in further studies.
An emerging number of studies indicate that sweeteners—whether caloric or non-
caloric—can influence glycemic control both positively and negatively. Xylitol was found
to exert anti-hyperglycemic effects when given over a longer period of time in diabetic
rats, possibly via enhancing insulin-mediated glucose uptake and reducing intestinal
Nutrients 2021, 13, 174 18 of 21
glucose absorption [33]. Additionally, trophic effects on pancreatic islet cells and strong
anti-oxidative potential against T2D-associated oxidative stress could be shown in rodent
models [34,35]. Human studies measuring glucose levels in patients with diabetes before
and after regular administration of xylitol over a long period of time are not currently
available. In our study, after acute administration of xylitol in healthy volunteers only a
weak increase in blood glucose levels was observed.
Another important player in glycemic control is the pancreatic hormone glucagon—
a hormone produced in the α-cells of the pancreatic islets—which stimulates hepatic
glycogenolysis and gluconeogenesis in hypoglycemic states to restore glucose homeostasis,
and in this way counter-balances insulin. Effects of acute or chronic intake of xylitol on
glucagon secretion have not been studied so far. In the current trial, we found no statis-
tically significant effects of different doses of xylitol on plasma glucagon concentrations
in this group of lean, healthy volunteers. However, the highest xylitol dose (35 g) lead
to numerically and statistically significant higher late (120 min) glucagon concentrations
compared to 17 g without a concomitant increase in plasma glucose concentrations. In
order to be able to make a definitive statement as to whether or not xylitol has any effect
on glucagon release, further studies would certainly be useful, preferably with longer
observation times (>180 min).
Gastrointestinal tolerance was not the main focus of this trial. However, as in litera-
ture gastrointestinal side-effects are often mentioned, we recorded them in detail. In our
previous trial, a rather high dose of xylitol (50 g) was used, which lead to gastrointestinal
side effects such as diarrhea in about 70% of the participants [5]. Previous studies with vol-
unteers unaccustomed to xylitol intake, recommend doses up to maximum 0.3 g/kg body
weight [36], which is slightly less than the highest dose (35 g) we administered in the cur-
rent trial. Moreover, the dose was rapidly applied (over 2 min) in a solution directly into the
stomach, which probably causes the greatest possible strain on the gastrointestinal system.
In spite of this, 35 g xylitol in 300 mL (the sweetness of this solution corresponds to around
30 g sucrose in 33cl, as found in sweet beverages) was very well tolerated, with subjective
increases in bowel sounds as the most common finding (while there was no abdominal
pain, vomiting, nausea, diarrhea, or flatulence). Other potential side effects associated with
sweetener consumption are alterations in uric acid and blood lipid concentrations. Uric
acid has been associated with obesity and metabolic syndrome as well as chronic kidney
disease and arterial hypertension [8]. Elevation of uric acid after oral intake of 50 g xylitol
has been described by Forster et al. in 1971 [9]. Additionally, intravenous administration of
xylitol solutions resulted in an increase in plasma uric acid [10]. In chronic exposition trials
with insulin-dependent children receiving 30 g xylitol/day an increase in uric acid was
found, however in healthy adult volunteers, 80–100 g of xylitol/day for 18 days had no
effect on uric acid, and in the Turku studies with chronic xylitol exposition over 2 years,
no effect on uric acid was found either [11,12]. In our trial, we found a 36% increase in
uric acid concentrations within the first 30 min which did not return to baseline values
until the last blood sample was taken after 120 min. Although mean serum uric acid levels
were within the normal range at all time points, the observed increase in uric acid has to be
investigated further, especially when consumed on a regular basis, and patients with gout
should probably be careful. At least in theory, also triglyceride synthesis might be affected
by ingestion of xylitol: The glycerol backbone-which is found in triglycerides-is a product
of the pentose-phosphate pathway. In this way, glycerol concentrations might increase
which might end up in triglyceride synthesis. Only a few studies have examined the effects
of xylitol intake on blood lipids in humans so far. Acute effects of enteral administration
of a xylitol containing formula in lean volunteers lead to an increase in triglycerides and
very low-density lipoproteins [13]. In trials with chronic exposition, no effect on blood
lipid concentrations could be found [12,14]. In the current trial, we examined blood lipid
profile after ingestion of the highest dose—35 g xylitol—and did not find any changes from
baseline values.
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Some potential limitations need to be addressed: In this trial, we studied acute effects
of single bolus doses of xylitol applied in a liquid in normal weight subjects who were
not used to these substances. Differential effects of long-term exposure on the secretion
of gut hormone and gastric emptying rates need to be investigated, as adaptive processes
cannot be ruled out. Furthermore, endogenous motilin secretion fluctuates in synchrony
with antral contractility of the migrating motor complex and reaches a peak just before
gastric phase III [31]. In this trial, blood samples were not taken in synchrony with phase
III, and therefore interpretation of motilin results is difficult and motilin responses ought
to be studied further. Finally, while we did not find any impact on blood lipids, and only
mild gastrointestinal symptoms even when applying the highest dose of xylitol in normal
weight healthy volunteers, future trials should probably include the target audience (obese
patients with metabolic syndrome) studied over a longer period of time (chronic intake)
with special attention to uric acid.
5. Conclusions
The present study shows that even low doses (7 to 35 g) of the natural sweetener xylitol
dose-dependently stimulate the secretion of CCK, aGLP-1 and PYY, and decelerate gastric
emptying rates in lean participants. Meanwhile, there is only little effect on plasma glucose
and insulin, and no effect on motilin, GIP, or blood lipid concentrations. Circulating uric
acid concentrations increase acutely following xylitol consumption, the clinical implications
are unclear and further research is necessary on this topic. Given as a single bolus dose
in a liquid, doses up to 35 g xylitol were well tolerated in this trial. With this study we
show that xylitol exhibits a combination of properties (weak effect on blood sugar levels
but significant release of satiation hormones) that render this sweetener an attractive
sugar substitute.
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